FDA approves Venetoclax for treatment of adult CLL/SLL

recently, the U.SFooddrug(http://Regulatory Authority (
FDA(http://) announced the approval of Venetoclax for the treatment of adult CLL/SLLThe CLL14 study was a multicenter, open label, randomized controlledtrial(http://involving 432 previously untreated CLL patients who were randomly assigned to receive the treatment of the Venableuzumab (VEN-G) or Aubin Yuto-bead monostya against and amphetamine sadontinic acid nitrogen mustard (GClb)The main endpoint of the study was the progression-free life span (PFS) assessed by the researchersSecondary endpoints include PFS assessed by an independent review committee, total mitigation rate, full mitigation rate, mitigation duration, total lifetime, event-free survival, time to the next CLL treatment, minimum residual disease status, and safetyThe results showed a statistically significant improvement in progression-free life span (PFS) in patients treated with VEN-G compared to patients treated with GClb (HR -0.33; 95% CI: 0.22-0.51; p 0.0001)The total remission rate was 85% in patients receiving VEN-G, and 71% in patients receiving GClb (p-0.0007)the trial also demonstrated a statistically significant improvement in the rate of negative trace residual disease (less than one CLL cell per 104 white blood cells) in bone marrow and peripheral blood 　　Adverse reactions in Patients with CLL/SLL, the most common adverse reactions (-20%) included neutrophil reduction, platelet reduction, anemia, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue and edema when Vinatok combined with Aubin Yutozumab, rituximatributoora, or monotherapy